Skip to content

April 28, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Other
Seaport and Hemab target $180m IPOs as biotech listings accumulate

Other

Seaport and Hemab target $180m IPOs as biotech listings accumulate

Pharmaceutical Technology

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

Pharmaceutical Technology

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Read full story

Post navigation

Previous: Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Next: Novartis shares fall as Entresto sales weaken

Related Stories

Other

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

pharminent April 27, 2026

Other

New NIHR-funded TRC for Parkinson’s disease

pharminent April 27, 2026

Other

UK biotech could be bound for recovery, BIA report reveals

pharminent April 27, 2026

You May Have Missed

Clinical Data

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

pharminent April 28, 2026

Clinical Data

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

pharminent April 28, 2026

M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

pharminent April 28, 2026

Regulatory

GSK eyes October FDA verdict on chronic hep B drug

pharminent April 28, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.